PharmaJet partners with Serum Institute to launch needle-free MMR vaccine.
PharmaJet, a maker of needle-free injection technology, announced its partnership with Serum Institute of India, the world’s largest vaccine manufacturer, is commercializing needle-free delivery of the MMR vaccine using the Stratis 0.5mL needle-free injection system.
The recently completed Phase IV clinical study, supported by the Gates Foundation and PATH, included 300+ children aged 15 – 18 months over a 12-month period. The results showed comparable non-inferiority performance and safety to that of the traditional needle and syringe. The newly labeled MMR vaccine TRESIVAC NF (needle-free) is expected to be available in early 2017.
Measles is a leading cause of childhood deaths globally, with 3 million cases of Measles diagnosed and nearly 1 million deaths each year. In India, it is estimated that 500 children die every day because of Measles. The vaccination coverage against Measles in India averages 66 percent, with rates below 50 percent in many parts of the country1.
“The PharmaJet device offers a safe, fast and easy alternative to traditional needle and syringe. Making needle-free an available alternative for the MMR vaccine has the potential to increase immunization rates and save lives,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.
1 Serum Institute of India website, Health FAQ – Measles, https://www.seruminstitute.com/content/faq_measles.htm
(Source: PR Newswire)
Filed Under: Drug Discovery